Pancreatic Cancer Research

ResearcherJikei University School of MedicineActive in the last 2 years

Koichiro Haruki

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-1686-3228; OpenAlex author ID A5037753214, A5114083949. Sources: OpenAlex.

Their work

Papers
53 (first author 6, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
36
Papers, trials and grants by year

2011: 2 papers · 2012: 1 paper · 2013: 4 papers · 2014: 1 paper · 2015: 2 papers · 2016: 4 papers · 2017: 1 paper · 2018: 5 papers · 2019: 2 papers · 2020: 1 paper · 2021: 3 papers · 2022: 2 papers · 2023: 4 papers · 2024: 5 papers · 2025: 9 papers · 2026: 7 papers

Papers 50 of 53

  1. Number of Liver Metastases Stratifies Prognosis in Synchronous Metastatic Pancreatic Cancer. First author DOI 10.1002/wjs.70666↗
  2. The Goddard score for emphysema predicts the postoperative prognosis in pancreatic cancer. Co-author DOI 10.1007/s00595-025-03188-7↗
  3. Prognostic stratification of unresectable locally advanced pancreatic cancer using a combination of inflammatory and nutritional indices: a retrospective cohor… Co-author DOI 10.1007/s00595-026-03344-7↗
  4. Preoperative predictors of early recurrence after neoadjuvant gemcitabine plus S-1 in resectable pancreatic cancer: a multicenter study. Co-author DOI 10.1007/s00595-026-03416-8↗
  5. Leveraging population-based health checkup data for pancreatic cancer risk stratification: toward pragmatic early detection Co-author DOI 10.1016/j.pan.2026.04.014↗
  6. Clinical and Functional Impact of CHMP3 in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-026-20340-w↗
  7. ASO Visual Abstract: Clinical and Functional Impact of CHMP3 in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-026-20399-5↗
  8. Abdominal aortic calcification volume as a preoperative prognostic predictor for pancreatic cancer. Co-author DOI 10.1007/s00595-024-02882-2↗
  9. The minimum apparent diffusion coefficient value on preoperative magnetic resonance imaging in resectable pancreatic cancer: a new prognostic factor for biolog… Co-author DOI 10.1007/s00595-025-03050-w↗
  10. The preoperative cachexia index predicts outcomes after pancreatic resection for resectable pancreatic cancer. Co-author DOI 10.1007/s00595-025-03088-w↗
  11. Timing of TS1 adjuvant chemotherapy as a prognostic factor in recurrent pancreatic cancer after surgery. Co-author DOI 10.1016/j.suronc.2024.102179↗
  12. Signal heterogeneity in apparent diffusion coefficient map of magnetic resonance imaging in resectable pancreatic cancer: a new prognostic factor for biologica… Co-author DOI 10.1016/j.suronc.2025.102270↗
  13. The Significant Impact of Fibrinogen-C-Reactive Protein-Albumin Ratio on the Long-Term Outcomes After Pancreatic Resection for Pancreatic Cancer. First author DOI 10.1097/mpa.0000000000002416↗
  14. Impact of Preoperative Osteosarcopenia and Postoperative Administration of Pancrelipase on the Prognosis of Borderline Resectable and Unresectable Locally Adva… Co-author DOI 10.1177/00031348241272420↗
  15. Prognostic Impact of a Decrease in Serum Carbohydrate Antigen 19-9 Levels After Preoperative Therapy for 4 Months or More for Borderline Resectable Pancreatic … Co-author DOI 10.1177/00031348241278016↗
  16. Changes in Skeletal Muscle Volume During Preoperative Chemotherapy Affect the Outcome of Pancreatic Cancer. Co-author DOI 10.1177/00031348241278021↗
  17. Prognostic impact of osteosarcopenia in patients undergoing pancreatic resection for pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00423-024-03315-x↗
  18. Prognostic significance of occult vertebral fracture in patients undergoing pancreatic resection for pancreatic cancer. Co-author DOI 10.1016/j.pan.2024.01.003↗
  19. The prognosis-based classification model in resectable pancreatic cancer. Co-author DOI 10.1016/j.suronc.2024.102035↗
  20. Effect of Risk Factor Score on Early Recurrence After Pancreatectomy for Invasive Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.21873/anticanres.16968↗
  21. Effect of Chemoradiotherapy on Locoregional Recurrence After Pancreatectomy for Pancreatic Cancer. Co-author DOI 10.21873/anticanres.17229↗
  22. Systemic inflammation adversely affects response to anamorelin in patients with pancreatic cancer. Co-author DOI 10.1007/s00520-023-08206-3↗
  23. Superior mesenteric vein/portal vein contact in preoperative imaging indicates biological malignancy in anatomically resectable pancreatic cancer. Co-author DOI 10.1016/j.suronc.2023.101998↗
  24. D1 Distal Pancreatectomy for Left-sided Pancreatic Ductal Adenocarcinoma Is Justifiable: A Propensity-score Matched Multicenter Study. Co-author DOI 10.21873/anticanres.16150↗
  25. Preoperative Therapy for Unresectable Locally Advanced Pancreatic Cancer for ≥6 Months Improves Prognosis After Pancreatectomy. Co-author DOI 10.21873/anticanres.16599↗
  26. The effectiveness of adjuvant chemotherapy for Stage I pancreatic cancer based on the UICC 8th edition. First author DOI 10.1007/s00423-022-02686-3↗
  27. Inhibition of lysosomal acid β-glucosidase induces cell apoptosis via impairing mitochondrial clearance in pancreatic cancer. Co-author DOI 10.1093/carcin/bgac060↗
  28. The novel index using preoperative C-reactive protein and neutrophil-to-lymphocyte ratio predicts poor prognosis in patients with pancreatic cancer. First author DOI 10.1007/s10147-021-01964-2↗
  29. Impact of osteopenia on surgical and oncological outcomes in patients with pancreatic cancer. Co-author DOI 10.1007/s10147-021-01986-w↗
  30. Inhibition of acid ceramidase elicits mitochondrial dysfunction and oxidative stress in pancreatic cancer cells. Co-author DOI 10.1111/cas.15123↗
  31. Prognostic Factors in Patients With Recurrent Pancreatic Cancer: A Multicenter Database Analysis. Co-author DOI 10.21873/anticanres.13952↗
  32. Incidental abdominal lymph node metastases from a known breast cancer in resected specimen of invasive pancreatic ductal adenocarcinoma: report of a case. First author DOI 10.1007/s13691-019-00382-6↗
  33. Combination of Distance from Superior Mesenteric Artery and Serum CA19-9 as a Novel Prediction of Local Recurrence in Patients With Pancreatic Cancer Following… Co-author DOI 10.21873/anticanres.13264↗
  34. Glycogen synthase kinase-3β activity plays a key role in the antitumor effect of nafamostat mesilate in pancreatic cancer cells. Co-author DOI 10.1002/ags3.12025↗
  35. Pomalidomide promotes chemosensitization of pancreatic cancer by inhibition of NF-κB. Co-author DOI 10.18632/oncotarget.24577↗
  36. Pomalidomide enhanced gemcitabine and nab-paclitaxel on pancreatic cancer both in vitro and in vivo. Co-author DOI 10.18632/oncotarget.24608↗
  37. Effects of ω-3 Fatty Acid Supplementation in Patients with Bile Duct or Pancreatic Cancer Undergoing Chemotherapy. Co-author DOI 10.21873/anticanres.12485↗
  38. C-Reactive Protein-based Prognostic Measures Are Superior at Predicting Survival Compared with Peripheral Blood Cell Count-based Ones in Patients After Curativ… First author DOI 10.21873/anticanres.13013↗
  39. Preoperative Platelet-to-Albumin Ratio Predicts Prognosis of Patients with Pancreatic Ductal Adenocarcinoma After Pancreatic Resection. Co-author DOI 10.21873/anticanres.11378↗
  40. The C-reactive Protein to Albumin Ratio Predicts Long-Term Outcomes in Patients with Pancreatic Cancer After Pancreatic Resection. Co-author DOI 10.1007/s00268-016-3491-4↗
  41. Dual inhibition of nuclear factor kappa-B and Mdm2 enhance the antitumor effect of radiation therapy for pancreatic cancer. Co-author DOI 10.1016/j.canlet.2015.10.034↗
  42. New treatment strategy with nuclear factor-κB inhibitor for pancreatic cancer. Co-author DOI 10.1016/j.jss.2016.06.047↗
  43. Comprehensive assessment of the prognosis of pancreatic cancer: peripheral blood neutrophil-lymphocyte ratio and immunohistochemical analyses of the tumour sit… Co-author DOI 10.3109/00365521.2015.1121515↗
  44. Preoperative platelet to lymphocyte ratio predicts outcome of patients with pancreatic ductal adenocarcinoma after pancreatic resection. Co-author DOI 10.1016/j.surg.2015.03.043↗
  45. Negative Impact of Preoperative Endoscopic Biliary Drainage on Prognosis of Pancreatic Ductal Adenocarcinoma After Pancreaticoduodenectomy. Co-author PMID 26254410↗
  46. Postoperative peripheral absolute blood lymphocyte-to-monocyte ratio predicts therapeutic outcome after pancreatic resection in patients with pancreatic adenoc… Co-author PMID 25202109↗
  47. Nuclear factor κB activity correlates with the progression and prognosis of pancreatic cancer in a mouse model. Co-author DOI 10.1007/s00595-012-0279-5↗
  48. Combination chemotherapy of serine protease inhibitor nafamostat mesilate with oxaliplatin targeting NF-κB activation for pancreatic cancer. Co-author DOI 10.1016/j.canlet.2013.01.019↗
  49. Inhibition of nuclear factor kappa-B enhances the antitumor effect of combination treatment with tumor necrosis factor-alpha gene therapy and gemcitabine for p… Co-author DOI 10.1016/j.jamcollsurg.2012.09.016↗
  50. Negative impact of fresh-frozen plasma transfusion on prognosis of pancreatic ductal adenocarcinoma after pancreatic resection. Co-author PMID 24023348↗

Closest collaborators

The 25 strongest of 36 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yoshihiro Shirai · 39 shared papers, 2014–2026 · strength 6.62
  2. Kenei Furukawa · 40 shared papers, 2011–2026 · strength 6.41
  3. Toru Ikegami · 29 shared papers, 2021–2026 · strength 6.15
  4. Masashi Tsunematsu · 21 shared papers, 2022–2026 · strength 4.64
  5. Shinji Onda · 21 shared papers, 2018–2026 · strength 4.39
  6. Michinori Matsumoto · 18 shared papers, 2019–2026 · strength 3.82
  7. Mitsuru Yanagaki · 14 shared papers, 2021–2026 · strength 3.08
  8. Ryoga Hamura · 17 shared papers, 2018–2026 · strength 2.94
  9. Takeshi Gocho · 18 shared papers, 2012–2026 · strength 2.93
  10. Tomohiko Taniai · 12 shared papers, 2019–2026 · strength 2.42
  11. Norimitsu Okui · 9 shared papers, 2023–2026 · strength 2.03
  12. Tadashi Uwagawa · 11 shared papers, 2018–2026 · strength 1.91
  13. Tadashi Uwagawa · 17 shared papers, 2011–2025 · strength 1.82
  14. Taro Sakamoto · 11 shared papers, 2015–2026 · strength 1.67
  15. Yoshiaki Tanji · 7 shared papers, 2023–2026 · strength 1.63
  16. Hiroaki Shiba · 22 shared papers, 2011–2022 · strength 1.50
  17. Kyohei Abe · 8 shared papers, 2018–2025 · strength 1.44
  18. Katsuhiko K. Yanaga · 22 shared papers, 2011–2020 · strength 1.36
  19. Yosuke Igarashi · 5 shared papers, 2024–2026 · strength 1.22
  20. Yuki Fujiwara · 19 shared papers, 2011–2022 · strength 1.12
  21. Takashi Horiuchi · 10 shared papers, 2015–2022 · strength 0.78
  22. Yuta Yamada · 3 shared papers, 2024–2026 · strength 0.74
  23. Shuichi Fujioka · 4 shared papers, 2022–2025 · strength 0.70
  24. Shunta Ishizaki · 3 shared papers, 2023–2025 · strength 0.63
  25. Takao Ohtsuka · 1 shared paper, 2026 · strength 0.50

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.